Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.728190
Keywords
systemic lupus erythematosus; mesenchymal stem cells; immunomodulation; transplantation; inefficacy; modification
Categories
Funding
- National Natural Science Foundation of China [82070757]
- Project of Dengfeng Plan from Guangdong Medical University
- Department of established positions for the Zhujiang Scholar from Guangdong Medical University
- Guangdong Basic and Applied Basic Research Foundation [2019A1515012203]
- Zhanjiang City Program for Tackling Key Problems in Science and Technology [2019B01179]
Ask authors/readers for more resources
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with unclear pathogenesis and lack of effective treatments. Mesenchymal stem cell (MSC) therapy has shown promise in treating refractory SLE by modulating immune cells, but its effectiveness and safety in SLE patients require further validation through experimental and clinical evidence.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Although previous studies have demonstrated that SLE is related to the imbalance of cells in the immune system, including B cells, T cells, and dendritic cells, etc., the mechanisms underlying SLE pathogenesis remain unclear. Therefore, effective and low side-effect therapies for SLE are lacking. Recently, mesenchymal stem cell (MSC) therapy for autoimmune diseases, particularly SLE, has gained increasing attention. This therapy can improve the signs and symptoms of refractory SLE by promoting the proliferation of Th2 and Treg cells and inhibiting the activity of Th1, Th17, and B cells, etc. However, MSC therapy is also reported ineffective in some patients with SLE, which may be related to MSC- or patient-derived factors. Therefore, the therapeutic effects of MSCs should be further confirmed. This review summarizes the status of MSC therapy in refractory SLE treatment and potential reasons for the ineffectiveness of MSC therapy from three perspectives. We propose various MSC modification methods that may be beneficial in enhancing the immunosuppression of MSCs in SLE. However, their safety and protective effects in patients with SLE still need to be confirmed by further experimental and clinical evidence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available